Dan Lu, Tong Lu, Mark Stroh, Richard A Graham, Priya Agarwal, Luna Musib, Chi-Chung Li, Bert L Lum, Amita Joshi. Cancer Chemother Pharmacol 2016
Times Cited: 35
Times Cited: 35
Times Cited
Times Co-cited
Similarity
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.
Jeffrey R Sachs, Kapil Mayawala, Satvik Gadamsetty, Soonmo Peter Kang, Dinesh P de Alwis. Clin Cancer Res 2016
Jeffrey R Sachs, Kapil Mayawala, Satvik Gadamsetty, Soonmo Peter Kang, Dinesh P de Alwis. Clin Cancer Res 2016
25
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Pasi A Jänne, Geoffrey Kim, Alice T Shaw, Rajeshwari Sridhara, Richard Pazdur, Amy E McKee. Clin Cancer Res 2016
Pasi A Jänne, Geoffrey Kim, Alice T Shaw, Rajeshwari Sridhara, Richard Pazdur, Amy E McKee. Clin Cancer Res 2016
25
Optimizing dosing of oncology drugs.
L Minasian, O Rosen, D Auclair, A Rahman, R Pazdur, R L Schilsky. Clin Pharmacol Ther 2014
L Minasian, O Rosen, D Auclair, A Rahman, R Pazdur, R L Schilsky. Clin Pharmacol Ther 2014
17
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
K Venkatakrishnan, L E Friberg, D Ouellet, J T Mettetal, A Stein, I F Trocóniz, R Bruno, N Mehrotra, J Gobburu, D R Mould. Clin Pharmacol Ther 2015
K Venkatakrishnan, L E Friberg, D Ouellet, J T Mettetal, A Stein, I F Trocóniz, R Bruno, N Mehrotra, J Gobburu, D R Mould. Clin Pharmacol Ther 2015
14
Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
Julie M Bullock, Atiqur Rahman, Qi Liu. Clin Cancer Res 2016
Julie M Bullock, Atiqur Rahman, Qi Liu. Clin Cancer Res 2016
15
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
C Liu, J Yu, H Li, J Liu, Y Xu, P Song, Q Liu, H Zhao, J Xu, V E Maher,[...]. Clin Pharmacol Ther 2017
C Liu, J Yu, H Li, J Liu, Y Xu, P Song, Q Liu, H Zhao, J Xu, V E Maher,[...]. Clin Pharmacol Ther 2017
11
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, Khaled Bouri, Michael L Lanthier, Rachel E Sherman. JAMA 2014
Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, Khaled Bouri, Michael L Lanthier, Rachel E Sherman. JAMA 2014
11
Determining the optimal dose in the development of anticancer agents.
Ron H J Mathijssen, Alex Sparreboom, Jaap Verweij. Nat Rev Clin Oncol 2014
Ron H J Mathijssen, Alex Sparreboom, Jaap Verweij. Nat Rev Clin Oncol 2014
11
Advancing Clinical Trials to Streamline Drug Development.
Susan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M LoRusso, Eric H Rubin. Clin Cancer Res 2015
Susan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M LoRusso, Eric H Rubin. Clin Cancer Res 2015
13
Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi,[...]. Clin Transl Sci 2016
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi,[...]. Clin Transl Sci 2016
15
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
J Wang, P Song, S Schrieber, Q Liu, Q Xu, G Blumenthal, L Amiri Kordestani, P Cortazar, A Ibrahim, R Justice,[...]. Clin Pharmacol Ther 2014
J Wang, P Song, S Schrieber, Q Liu, Q Xu, G Blumenthal, L Amiri Kordestani, P Cortazar, A Ibrahim, R Justice,[...]. Clin Pharmacol Ther 2014
8
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
Nicholas S Downing, Nilay D Shah, Jenerius A Aminawung, Alison M Pease, Jean-David Zeitoun, Harlan M Krumholz, Joseph S Ross. JAMA 2017
Nicholas S Downing, Nilay D Shah, Jenerius A Aminawung, Alison M Pease, Jean-David Zeitoun, Harlan M Krumholz, Joseph S Ross. JAMA 2017
8
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
20
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.
Rashmi R Shah, Joel Morganroth. Drug Saf 2015
Rashmi R Shah, Joel Morganroth. Drug Saf 2015
5
Rare cancer trial design: lessons from FDA approvals.
Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur. Clin Cancer Res 2012
Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur. Clin Cancer Res 2012
5
Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Sariah Liu, Razelle Kurzrock. Semin Oncol 2015
Sariah Liu, Razelle Kurzrock. Semin Oncol 2015
12
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Amita Patnaik, S Peter Kang, Drew Rasco, Kyriakos P Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino,[...]. Clin Cancer Res 2015
Amita Patnaik, S Peter Kang, Drew Rasco, Kyriakos P Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino,[...]. Clin Cancer Res 2015
5
Failures in Phase III: Causes and Consequences.
Bostjan Seruga, Alberto Ocana, Eitan Amir, Ian F Tannock. Clin Cancer Res 2015
Bostjan Seruga, Alberto Ocana, Eitan Amir, Ian F Tannock. Clin Cancer Res 2015
5
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
Paul Morgan, Piet H Van Der Graaf, John Arrowsmith, Doug E Feltner, Kira S Drummond, Craig D Wegner, Steve D A Street. Drug Discov Today 2012
Paul Morgan, Piet H Van Der Graaf, John Arrowsmith, Doug E Feltner, Kira S Drummond, Craig D Wegner, Steve D A Street. Drug Discov Today 2012
5
Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
Shinji Yamazaki. AAPS J 2013
Shinji Yamazaki. AAPS J 2013
6
Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Marc R Theoret, Lee H Pai-Scherf, Meredith K Chuk, Tatiana M Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G Kluetz, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2015
Marc R Theoret, Lee H Pai-Scherf, Meredith K Chuk, Tatiana M Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G Kluetz, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2015
7
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Lorea Bueno, Dinesh P de Alwis, Celine Pitou, Jonathan Yingling, Michael Lahn, Sophie Glatt, Iñaki F Trocóniz. Eur J Cancer 2008
Lorea Bueno, Dinesh P de Alwis, Celine Pitou, Jonathan Yingling, Michael Lahn, Sophie Glatt, Iñaki F Trocóniz. Eur J Cancer 2008
5
A time to event tutorial for pharmacometricians.
Nick Holford. CPT Pharmacometrics Syst Pharmacol 2013
Nick Holford. CPT Pharmacometrics Syst Pharmacol 2013
5
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
Roelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, Frank G A Jansman. Lancet Oncol 2014
Roelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, Frank G A Jansman. Lancet Oncol 2014
5
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Mark G Qian, Gerald Falchook, Richard Labotka,[...]. Br J Clin Pharmacol 2016
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Mark G Qian, Gerald Falchook, Richard Labotka,[...]. Br J Clin Pharmacol 2016
7
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Neeraj Gupta, Michael J Hanley, R Donald Harvey, Ashraf Badros, Brea Lipe, Vishal Kukreti, Jesus Berdeja, Huyuan Yang, Ai-Min Hui, Mark Qian,[...]. Br J Haematol 2016
Neeraj Gupta, Michael J Hanley, R Donald Harvey, Ashraf Badros, Brea Lipe, Vishal Kukreti, Jesus Berdeja, Huyuan Yang, Ai-Min Hui, Mark Qian,[...]. Br J Haematol 2016
5
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Neeraj Gupta, Richard Labotka, Guohui Liu, Ai-Min Hui, Karthik Venkatakrishnan. Invest New Drugs 2016
Neeraj Gupta, Richard Labotka, Guohui Liu, Ai-Min Hui, Karthik Venkatakrishnan. Invest New Drugs 2016
13
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson,[...]. N Engl J Med 2016
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson,[...]. N Engl J Med 2016
5
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Paul G Richardson, Philippe Moreau, Jacob P Laubach, Neeraj Gupta, Ai-Min Hui, Kenneth C Anderson, Jesús F San Miguel, Shaji Kumar. Future Oncol 2015
Paul G Richardson, Philippe Moreau, Jacob P Laubach, Neeraj Gupta, Ai-Min Hui, Kenneth C Anderson, Jesús F San Miguel, Shaji Kumar. Future Oncol 2015
10
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond S M Wong, Chor Sang Chim, Michael J Hanley, Huyuan Yang, Karthik Venkatakrishnan,[...]. J Hematol Oncol 2015
Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond S M Wong, Chor Sang Chim, Michael J Hanley, Huyuan Yang, Karthik Venkatakrishnan,[...]. J Hematol Oncol 2015
6
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Paul G Richardson, Rachid Baz, Michael Wang, Andrzej J Jakubowiak, Jacob P Laubach, R Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu,[...]. Blood 2014
Paul G Richardson, Rachid Baz, Michael Wang, Andrzej J Jakubowiak, Jacob P Laubach, R Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu,[...]. Blood 2014
5
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Neeraj Gupta, Paul M Diderichsen, Michael J Hanley, Deborah Berg, Helgi van de Velde, R Donald Harvey, Karthik Venkatakrishnan. Clin Pharmacokinet 2017
Neeraj Gupta, Paul M Diderichsen, Michael J Hanley, Deborah Berg, Helgi van de Velde, R Donald Harvey, Karthik Venkatakrishnan. Clin Pharmacokinet 2017
6
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, Craig B Reeder, James R Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu,[...]. Blood 2014
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, Craig B Reeder, James R Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu,[...]. Blood 2014
5
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Neeraj Gupta, Yuan Zhao, Ai-Min Hui, Dixie-Lee Esseltine, Karthik Venkatakrishnan. Br J Clin Pharmacol 2015
Neeraj Gupta, Yuan Zhao, Ai-Min Hui, Dixie-Lee Esseltine, Karthik Venkatakrishnan. Br J Clin Pharmacol 2015
5
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio,[...]. Lancet Oncol 2014
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio,[...]. Lancet Oncol 2014
5
50
Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.
Lei Nie, Eric H Rubin, Nitin Mehrotra, José Pinheiro, Laura L Fernandes, Amit Roy, Stuart Bailey, Dinesh P de Alwis. Clin Cancer Res 2016
Lei Nie, Eric H Rubin, Nitin Mehrotra, José Pinheiro, Laura L Fernandes, Amit Roy, Stuart Bailey, Dinesh P de Alwis. Clin Cancer Res 2016
5
Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology.
K Yoshida, N Budha, J Y Jin. Clin Pharmacol Ther 2017
K Yoshida, N Budha, J Y Jin. Clin Pharmacol Ther 2017
6
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.
B Darpo, C Benson, C Dota, G Ferber, C Garnett, C L Green, V Jarugula, L Johannesen, J Keirns, K Krudys,[...]. Clin Pharmacol Ther 2015
B Darpo, C Benson, C Dota, G Ferber, C Garnett, C L Green, V Jarugula, L Johannesen, J Keirns, K Krudys,[...]. Clin Pharmacol Ther 2015
5
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, Jeffrey S Weber. Clin Cancer Res 2013
Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, Jeffrey S Weber. Clin Cancer Res 2013
5
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, Matthew Riggs, Jonathan French, Xin Wang, Shweta Vadhavkar, Melanie Smitt, Silke Hoersch, Alexander Strasak,[...]. Br J Clin Pharmacol 2017
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, Matthew Riggs, Jonathan French, Xin Wang, Shweta Vadhavkar, Melanie Smitt, Silke Hoersch, Alexander Strasak,[...]. Br J Clin Pharmacol 2017
16
PBPK modeling and simulation in drug research and development.
Xiaomei Zhuang, Chuang Lu. Acta Pharm Sin B 2016
Xiaomei Zhuang, Chuang Lu. Acta Pharm Sin B 2016
5
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Neeraj Gupta, Yeamin Huh, Matthew M Hutmacher, Sean Ottinger, Ai-Min Hui, Karthik Venkatakrishnan. Cancer Chemother Pharmacol 2015
Neeraj Gupta, Yeamin Huh, Matthew M Hutmacher, Sean Ottinger, Ai-Min Hui, Karthik Venkatakrishnan. Cancer Chemother Pharmacol 2015
10
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon M Blumenthal, David C Turner, Claire Li, Malidi Ahamadi,[...]. J Pharmacokinet Pharmacodyn 2017
Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon M Blumenthal, David C Turner, Claire Li, Malidi Ahamadi,[...]. J Pharmacokinet Pharmacodyn 2017
5
The combination of exposure-response and case-control analyses in regulatory decision making.
Jun Yang, Hong Zhao, Christine Garnett, Atiqur Rahman, Jogarao V Gobburu, William Pierce, Genevieve Schechter, Jeffery Summers, Patricia Keegan, Brian Booth,[...]. J Clin Pharmacol 2013
Jun Yang, Hong Zhao, Christine Garnett, Atiqur Rahman, Jogarao V Gobburu, William Pierce, Genevieve Schechter, Jeffery Summers, Patricia Keegan, Brian Booth,[...]. J Clin Pharmacol 2013
5
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
5
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
Stephanie Faucette, Santosh Wagh, Ashit Trivedi, Karthik Venkatakrishnan, Neeraj Gupta. Clin Transl Sci 2018
Stephanie Faucette, Santosh Wagh, Ashit Trivedi, Karthik Venkatakrishnan, Neeraj Gupta. Clin Transl Sci 2018
9
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Neeraj Gupta, Huyuan Yang, Michael J Hanley, Steven Zhang, Rachael Liu, Shaji Kumar, Paul G Richardson, Tomas Skacel, Karthik Venkatakrishnan. Target Oncol 2017
Neeraj Gupta, Huyuan Yang, Michael J Hanley, Steven Zhang, Rachael Liu, Shaji Kumar, Paul G Richardson, Tomas Skacel, Karthik Venkatakrishnan. Target Oncol 2017
12
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.